Gut check: kidney Drug's hidden impact on your microbiome
NCT ID NCT05965440
First seen Feb 21, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study looked at how dapagliflozin, a drug already used for kidney disease, changes the gut bacteria in people with chronic kidney disease who do not have diabetes. Researchers measured gut bacteria diversity and related toxins in the blood before and after 12 weeks of treatment. The goal was to understand if changes in gut bacteria help explain the drug's kidney-protective effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nephrology department, Hôpital Lyon Sud, Hospices Civils de Lyon
Lyon, France
Conditions
Explore the condition pages connected to this study.